BioCentury
ARTICLE | Finance

Highlights of weekly biotech stock moves

Regulatory, clinical and other milestones

March 17, 2014 7:00 AM UTC

Keryx Biopharmaceuticals Inc. (NASDAQ:KERX) was off $0.16 to $15.11 last week after submitting an MAA to EMA for Zerenex ferric citrate to treat hyperphosphatemia in dialysis dependent and non-dialysis dependent patients with chronic kidney disease (CKD).

The product is under FDA review for CKD in dialysis patients, with a June 7 PDUFA date. In January, Japan approved the product as Riona...